Latest Genzyme Corporation Stories
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan.
Former head of rare diseases at Genzyme brings a 20-year track record of delivering successful, innovative products to patients throughout the world PHILADELPHIA, Dec.
- Stowe to be Joined by Leading Neurologists and People Living with the Disease for Live Events Nationwide - CAMBRIDGE, Mass., Oct.
- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated
Minerva president Rogerio Vivaldi and board chairman Marc Beer leading strategy to advance pipeline of novel therapies targeting applications in neuropsychiatry. CAMBRIDGE, Mass., March 5,
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc.
TAMPA, Fla., Dec. 30, 2013 /PRNewswire/ -- Whistleblower Law Firm, P.L.
As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy
- In medieval musical notation, a sign or neume denoting a shake or trill.